4-甲氧基噻吩-3-羧酸 | 71050-40-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-甲氧基噻吩-3-羧酸
• 英文名称: 4-methoxythiophene-3-carboxylic acid
• CAS: 71050-40-3
• 化学式: C₆H₆O₃S
• mdl: MFCD00067997
• 分子量: 158.178
• InChiKey: KEYPLCJVNVJJQK-UHFFFAOYSA-N

物化性质

• 熔点：
  105 °C
• 沸点：
  295.7±20.0 °C(Predicted)
• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光、干燥密封。

SDS

Name:	4-Methoxythiophene-3-carboxylic acid 95+% Material Safety Data Sheet
Synonym:
CAS:	71050-40-3

Section 1 - Chemical Product MSDS Name:4-Methoxythiophene-3-carboxylic acid 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
71050-40-3	4-Methoxythiophene-3-carboxylic acid	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 71050-40-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 101 - 105 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H6O3S
Molecular Weight: 158

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 71050-40-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methoxythiophene-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 71050-40-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 71050-40-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 71050-40-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-甲氧基噻吩-3-羧酸是一种羧酸类衍生物，可作为有机合成中的重要中间体。

反应信息

• 作为反应物：
  描述：

  4-甲氧基噻吩-3-羧酸 在 磺酰氯 作用下， 以 氯仿 为溶剂， 生成 5-氯-4-甲氧基噻吩-3-羧酸
  参考文献：
  名称：

  Organic compounds and their use as pharmaceuticals

  摘要：

  化学式为##STR1##的药物化合物，其中R.sup.1，R.sup.2和R.sup.3独立地是氢，羟基，卤素，硝基，氨基，C.sub.2-5酰胺基，C.sub.1-4烷基，--CHO，--CH.sub.2 OH，--CH.sub.2 OC.sub.1-4烷基，--COOH，--COC.sub.1-3烷基，--CH(OH)C.sub.1-3烷基，C.sub.1-4烷氧基，C.sub.2-4烯基氧基，C.sub.1-4烷基硫基，C.sub.1-4烷基磺酰基，C.sub.1-4烷基磺基，N-取代的杂环基，可选择取代的苯基，可选择取代的苯基硫基，可选择取代的苯基磺酰基，可选择取代的苯基磺胺基，或者R.sup.1和R.sup.2共同形成一个C.sub.3-5烷基桥；前提是R.sup.2和R.sup.3中至少有一个是C.sub.1-4烷氧基或C.sub.2-4烯基氧基；X为(i)--(CH.sub.2).sub.n N(R.sup.4).sub.2，其中每个R.sup.4独立地是C.sub.1-4烷基，C.sub.2-4烯基或可选择取代的C.sub.6 H.sub.5 CH.sub.2 --，n为1, 2或3，或者(ii)一个含有一个或两个氮原子的5-到8-成员的脂环基，直接连接到酰胺氮或通过一个C.sub.1-3烷基链连接；以及其盐和酯。

  公开号：

  US05015656A1
• 作为产物：
  描述：

  4-溴-噻吩-3-羧酸甲酯 在 sodium hydroxide 、 sodium iodide 、 copper(II) oxide 作用下， 以 甲醇 为溶剂， 反应 68.25h， 生成 4-甲氧基噻吩-3-羧酸
  参考文献：
  名称：

  一类新型的，有效的，选择性的和口服活性的前列腺素D2受体拮抗剂的各种衍生物的合成和生物活性。2.6，6-二甲基双环[3.1.1]庚烷衍生物。

  摘要：

  在较早的论文中，我们报道了以双环[2.2.1]庚烷环系统为前列腺素骨架的新型前列腺素D（2）（PGD（2））受体拮抗剂是一种有效的新型抗过敏剂，可抑制各种过敏性炎症诸如在结膜炎和哮喘模型中观察到的反应。在本研究中，我们合成了具有6,6-二甲基双环[3.1.1]庚烷环系统的PGD（2）受体拮抗剂。与具有磺酰胺基的双环[2.2.1]庚烷环系统的那些相反，这些衍生物具有酰胺部分。具有6,6-二甲基双环[3.1.1]庚烷环的衍生物在PGD（2）受体结合和cAMP形成分析中也显示出强大的活性。在诸如过敏性鼻炎，结膜炎和哮喘模型等体内分析中，这些系列的衍生物显示出优异的药理特性。特别地，化合物45在过敏性鼻炎和哮喘模型中也有效抑制了嗜酸性粒细胞的浸润。该化合物（45，S-5751）现在正被开发为一种有前途的抗过敏药物候选物。

  DOI：

  10.1021/jm0205189

文献信息

• [EN] SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS<br/>[FR] INDOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU VIRUS DE L'HEPATITE C (VHC)
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2004035571A1

  公开（公告）日：2004-04-29

  The present invention comprises indole-derivatives that are inhibitors of HCV. Composition comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.

  本发明涵盖了对HCV具有抑制作用的吲哚衍生物。还公开了包含这些化合物与药用可接受载体结合的组合物，以及使用这些化合物和组合物来抑制细胞中的HCV感染的方法，特别是用于治疗哺乳动物体内的HCV感染。
• Ru-catalysed C(sp²)–H vinylation/annulation of benzoic acids and alkynes: rapid access to medium-sized lactones
  作者：Xiao-Qiang Hu、Zi-Kui Liu、Ye-Xing Hou、Guodong Zhang、Yang Gao

  DOI：10.1039/d0cc07573f

  日期：——

  annulation of readily available benzoic acids and alkynes is reported for the first time. The carboxylate group acts as both a directing group and an internal nucleophilic reagent to facilitate a C(sp2)–H vinylation/annulation cascade. This reaction avoids the classically oxidative [4+2] annulation, allowing the efficient synthesis of a wide array of eight-membered lactones under oxidant-free conditions

  首次报道了前所未有的钌催化的易获得的苯甲酸和炔烃的[4 + 4]环化反应。羧酸盐基团既是直接基团又是内部亲核试剂，可促进C（sp 2）–H乙烯基化/环化级联反应。该反应避免了经典的[4 + 2]环氧化反应，可在无氧化剂条件下有效合成多种八元内酯。此外，该催化体系可以成功地扩展到[4 + 3]和[4 + 5]环空，以组装七元和九元内酯。
• Use of serotonin 5-HT1F agonists for the prevention of migraine
  申请人：ELI LILLY AND COMPANY

  公开号：EP0832650A3

  公开（公告）日：1998-09-02

  This invention provides methods for the prevention of migraine which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.

  这项发明提供了预防偏头痛的方法，包括向需要的哺乳动物施用一种5-HT1F受体激动剂。
• [EN] 4(SPIROPIPERIDINYL)METHYL SUBSTITUTED PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] 4(SPIROPIPERIDINYL)METHYL PYRROLIDINES SUBSTITUEES SERVANT DE MODULATEURS DE L'ACTIVITE DES RECEPTEURS DES CHIMIOKINES
  申请人：MERCK & CO INC

  公开号：WO2004058763A1

  公开（公告）日：2004-07-15

  3-Substituted pyrrolidines having a spiropiperidinylmethyl substituent on the 4-position of the ring are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

  在环的4位上具有螺环哌啶甲基取代基的3-取代吡咯烷可用作化学因子受体活性调节剂。具体来说，这些化合物可用作化学因子受体CCR-3和/或CCR-5的调节剂。
• Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
  申请人：ELI LILLY AND COMPANY

  公开号：EP0824917A3

  公开（公告）日：2000-08-30

  This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.

  这项发明提供了治疗或缓解普通感冒或过敏性鼻炎症状的方法，包括向需要的哺乳动物施用一种5-HT1F受体激动剂。